In the fourth activity of this CME Outfitters Snack series, expert faculty will individualize the selection of GLP-1 RA therapies based on patient-specific factors such as CV risk, weight management needs, and preferences for administration.
In the fifth activity of this CME Outfitters Snack series, expert faculty will assess dosing strategies and escalation best practices to optimize patient outcomes and foster therapy adherence. Faculty will model development of patient-centered counseling strategies that address concerns or misconceptions of GLP-1 RA therapies, including evidence-based benefits.
In the second activity of this CME Outfitters Snack series, expert faculty will differentiate current and emerging GLP-1 RA therapies based on their dosing schedules, administration methods, and glycemic and extra-glycemic benefits. Faculty will identify the mechanisms of action (MOAs) of GLP-1 RAs including their effects on key organ systems, including the pancreas, liver, brain, kidneys, and CV system.
In the third activity of this CME Outfitters Snack series, expert faculty will incorporate clinical trial evidence supporting the use of GLP-1 RAs in T2D management, including outcomes related to glucose control, CV safety, CKD, and tolerability. Faculty will model utilization of current treatment guidelines to implement GLP-1 RA therapy tailored to individual patient characteristics, including comorbidities, goals of care, and lifestyle considerations.
In the first activity of this CME Outfitters Snack series, expert faculty will identify the multifaceted impact of GLP-1 RA therapies on glycemic control, CV health, weight management, renal health, liver health, and overall T2D complication risk.
In this CME Outfitters Snack, expert faculty and a patient advocate will discuss clinical experience, study information, updates to guidelines, resources, and how to integrate sensitive and respectful discussions about anal cancer risk, prevention, and screening into everyday clinical workflows to improve outcomes for patients at high risk for anal cancer.
